Medicine has come tremendously far in the last century. In 1914, Penicillin had not yetbeen discovered and pneumonia and TB were causing a third of all deaths on theplanet1. Fast forward onehundred years and two world wars, and the world of medicine isunrecognizable.
GE believes thatthe future holds remarkable promise for increasing access to earlier diagnosisand treatment of diseases, refining healthcare quality and reducing healthcarecost. The ever-changing healthcare landscape has inspired GE to collaboratewith industry pioneers to design solutions focused on tackling critical population health challenges and economic issues. Each of these collaborations addresses a specific purpose or challenge in the healthcare industry.
Here are 5 examples of GE’s commitment to change the healthcare landscape for the better.
“The science of cell therapy is making significant strides, and there is no doubt about the consensus: this is set to revolutionize medicine,” said Kieran Murphy, President and CEO GE Healthcare Life Sciences.
The advent of this is not without challenges though. A relatively new area that involves taking cells and modifying them to fight disease more effectively—be it stroke, cancer or heart failure—cell therapies open up new possibilities. The UK Cell Therapy Catapult has announced that it will construct a £55 million manufacturing centre to aid in the progress of advanced therapies. GE Healthcare is doing its part by helping shape and develop a manufacturing ecosystem that supports development, production and distribution of these breakthrough medicines.
Find out more about their efforts on transforming cell therapies from the lab research to reality here.
(Dec 19, 2014)
Metastatic melanoma, the most deadly form of skin cancer, kills at least 76,000 people in a year2.This year GE Healthcare will work hand-in-hand with GSK in an unprecedented effort to further research on melanoma. GE Healthcare, through its affiliate Clarient, will use its expertise to certify laboratories and generate diagnostic data on metastatic melanoma patients. The first laboratories to do this important work are expected to be operational in several countries, including Brazil and Russia, by early 2015.
Find out how this partnership is set to open up new opportunities in the field of cancer research and improve patient care and personalized medicine around the world here.
(Dec 10, 2014)
The brain is one of the most undiscovered territories in our body3. The sheer complexity of the brain has led to the development of innovative new tools to enhance understanding of the brain’s function. It is hoped that the work on implantable devices to measure, record and interpret brain activity can lead to new discoveries about brain-related illnesses such as autism, Alzheimer’s and traumatic brain injury. GE Global Researcher, Jeffrey Ashe, partnered with Brown University to further study the electrical signals of the brain and using those to explore the control of assistive devices.
Find out how this study can be applied for future treatments related to brain injury here.
(July 3, 2014)
In a new collaboration, GE Healthcare and Takeda Group have announced that they will be joining efforts to develop new diagnostic techniques and drugs for liver fibrosis along with other liver diseases. Liver fibrosis is a dangerous symptom that affects a growing number of people worldwide, such as alcohol addiction, non-alcoholic fatty liver disease (NAFLD) and hepatitis. According to the World Health Organization, 20 million people worldwide are suffering from NAFLD and around 3% of the world’s population has hepatitis C. This collaboration is set to benefit the developing nations like the US, the UK and Japan, who are witnessing rapid ageing of their populations and will likely see a spike in liver disease.
Read more on their current efforts in developing technologies to help provide solutions for liver disease here.
(Nov 11, 2014)
Like a tree in the forest, the tissue in front of and behind a cancer can hide cancers on standard 2D digital mammography, limiting the radiologists’ ability to detect them.
Despite the many advantages that have been gained in the past years with mammography, it is estimated that 20 percent or more breast cancers are still being missed on digital mammograms. One reason for this is that cancers can be hidden by the normal tissues of the breast. Invented at the Massachusetts General Hospital, Boston, by one of the world’s leading experts in breast cancer detection and diagnosis, and developed in partnership with GE, Digital Breast Tomosynthesis technology helps reduce these problems.
Read more on the efforts taken between GE and the Massachusetts General Hospital in tackling breast cancer here.
(Sept 4, 2014)